Alzheimer's Disease News and Research

RSS

Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.

NIH increases funding through the BRAIN Initiative

The National Institutes of Health announces funding of more than 200 new awards, totaling over $220 million, through the Brain Research through Advancing Innovative Neurotechnologies Initiative, an exciting trans-agency effort to arm researchers with revolutionary tools to fundamentally understand the neural circuits that underlie the healthy and diseased brain.

2 Nov 2018

Insilico Medicine to present latest advances in drug development at Supply Side West Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in modern drug development at the Supply Side West Conference in Las Vegas, 8-9 of November.

2 Nov 2018

New form of therapy may stop or reverse progressive vision loss

A new form of therapy may halt or even reverse a form of progressive vision loss that, until now, has inevitably led to blindness.

1 Nov 2018

Integral Molecular wins NIH grant to initiate target discovery program for Alzheimer’s disease

Integral Molecular, the industry leader in membrane protein technologies, was awarded a Small Business Innovation Research grant from the NIH to initiate a target discovery program for Alzheimer's disease.

1 Nov 2018

Toxic protein assemblies found to play beneficial role in muscle generation

Toxic protein assemblies, or "amyloids," long considered to be key drivers in many neuromuscular diseases, also play a beneficial role in the development of healthy muscle tissue, University of Colorado Boulder researchers have found.

1 Nov 2018

Alzheimer's Association's Part the Cloud program funds innovative research on brain cells

Innovative research aimed to possibly rejuvenate brain cells will be explored by six international researchers with the goal of discovering effective drugs for people with early stage Alzheimer's disease and other dementias.

31 Oct 2018

Genetic defect linked to ALS causes sugar-starved cells to overproduce lipids

A genetic defect tied to a variety of neurodegenerative diseases and mental illnesses changes how cells starved of sugar metabolize fatty compounds known as lipids, a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health shows.

31 Oct 2018

Insilico to present its research in AI for drug discovery at BioCentury China HealthCare Summit

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its research in AI for drug discovery at BioCentury China HealthCare Summit in Shanghai, 13-14 of November.

31 Oct 2018

FDA approves ultra-high-field 7T Terra MRI scanner for clinical use

The ultra-high-field 7T Terra magnetic resonance imaging scanner at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute of the Keck School of Medicine of USC has received FDA approval for clinical use, opening up new avenues of care for patients with Alzheimer's disease, multiple sclerosis and other diseases that affect the brain.

31 Oct 2018

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

Nanoparticles that could reprogram a cancer patient's immune system inside their own body. Understanding a mysterious type of brain cell in the hopes of shedding new light on Alzheimer's disease. Reimagining nuclei, the DNA-storage compartments of our cells, as miniature lava lamps.

30 Oct 2018

UTHealth's Valentin Dragoi wins $1.6 million NIH award to unlock mysteries of the brain

Working to further the understanding of how the brain processes information, Valentin Dragoi, Ph.D., of The University of Texas Health Science Center at Houston has been awarded a three-year, $1.6 million award from the National Institutes of Health's Brain Research through Advancing Innovative Neurotechnologies Initiative.

30 Oct 2018

Insilico to present latest research on biomarkers at Investing in the Age of Longevity Conference

Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest advances in human aging biomarker development at the Investing in the Age of Longevity Conference in London, 1 of November.

30 Oct 2018

Exercise could reduce risk of falling for older adults with AD

Alzheimer's disease is a brain disease that causes changes that kill brain cells. AD is a type of dementia, which causes memory loss and problems with thinking and making decisions.

29 Oct 2018

Neuroene Therapeutics receives $1.5 million NIH grant to develop anti-seizure compound for epilepsy

Neuroene Therapeutics, a start-up company founded by mitochondrial biologist Sherine S. L. Chan, Ph.D. and medicinal chemist C. James Chou, Ph.D. of the Medical University of South Carolina, has received a $1.5 million NIH Phase II Small Business Innovation Research grant to optimize vitamin K analogues that could improve seizure control in patients with drug-resistant epilepsy.

29 Oct 2018

Studies show that non-invasive imaging can detect Alzheimer's disease

Results from two studies show that a new, non-invasive imaging device can see signs of Alzheimer's disease in a matter of seconds. The researchers show that the small blood vessels in the retina at the back of the eye are altered in patients with Alzheimer's.

29 Oct 2018

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD.

29 Oct 2018

Study finds weaker relationship between what older adults see and their brain activity

Forgetfulness and age-related memory lapses are a common complaint for many older adults, but what is still not understood is what causes these changes.

26 Oct 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Innovative supportive care model tackles burdensome symptoms, challenges of dementia

Individuals with dementia often experience burdensome symptoms such as agitation, aggression, anxiety and pain, but have difficulty with comprehension and communication, making it challenging for healthcare providers to provide appropriate treatment.

26 Oct 2018

UTA social work professors use NIH grant to find ways for reducing caregiver stress

Two UTA social work professors are using an NIH grant to find ways to reduce stress of families caring for loved ones with Alzheimer's disease.

26 Oct 2018

Alzheimer's Disease News and Research

Further Reading

NIH increases funding through the BRAIN Initiative

Insilico Medicine to present latest advances in drug development at Supply Side West Conference

New form of therapy may stop or reverse progressive vision loss

Integral Molecular wins NIH grant to initiate target discovery program for Alzheimer’s disease

Toxic protein assemblies found to play beneficial role in muscle generation

Alzheimer's Association's Part the Cloud program funds innovative research on brain cells

Genetic defect linked to ALS causes sugar-starved cells to overproduce lipids

Insilico to present its research in AI for drug discovery at BioCentury China HealthCare Summit

FDA approves ultra-high-field 7T Terra MRI scanner for clinical use

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

UTHealth's Valentin Dragoi wins $1.6 million NIH award to unlock mysteries of the brain

Insilico to present latest research on biomarkers at Investing in the Age of Longevity Conference

Exercise could reduce risk of falling for older adults with AD

Neuroene Therapeutics receives $1.5 million NIH grant to develop anti-seizure compound for epilepsy

Studies show that non-invasive imaging can detect Alzheimer's disease

Biogen and Eisai present detailed results from phase 1b study of aducanumab at CTAD meeting

Study finds weaker relationship between what older adults see and their brain activity

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Innovative supportive care model tackles burdensome symptoms, challenges of dementia

UTA social work professors use NIH grant to find ways for reducing caregiver stress

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News